Despite its acceptance as standard of care neary 25 years ago, barriers still exist that preclude patients from receiving breast conserving therapy (BCT), according to research presented at the ASCO 2014 Breast Cancer Symposium.
Researchers have developed a breathalyzer that can detect lung cancer and assess whether it is early or advanced, according to findings presented at the 2014 annual meeting of the American Society of Clinical Oncology.
New treatment options are available for advanced melanoma, according to three studies presented at the annual ASCO meeting.
In patients with triple-negative breast cancer (TNBC) who are BRCA1/2 mutation carriers, pathologic complete response (pCR) is not a surrogate for relapse-free survival, in contrast to those with non-BRCA mutations.
Immediately integrating cancer treatment and palliative care might improve survival at 1 year in patients with advanced cancers, suggest findings from the ENABLE III randomized controlled trial, presented at the 2014 ASCO Annual Meeting.
For patients with non-small-cell lung cancer who have relapsed after initial treatment, the addition of the anti-angiogenesis drug ramucirumab to standard docetaxel chemotherapy extends survival.
Enzalutamide, an oral androgen-receptor inhibitor, is superior to placebo for the treatment of metastatic prostate cancer before chemotherapy, according a study.
For premenopausal women with hormone receptor-negative early breast cancer treated with chemotherapy, goserelin can preserve ovarian function, according to a study presented at the annual ASCO meeting.
Family members caring for patients with advanced cancer benefit from early initiation of phone-based training and support.
In patients with breast cancer who had previously received monthly intravenous bisphosphonate therapy for bone metastases for a year or longer, maintenance zoledronic acid administered every 12 weeks was noninferior to every 4 weeks.
Reduced-dose intensity-modulated radiotherapy after complete clinical responses to induction chemotherapy for operable stage III/IVA, human papillomavirus (HPV)-positive head and neck cancer appears to be safe and might improve patients' quality of life.
Adult and young adult cancer survivors face cognitive and sexual late effects from cancer and its treatment, according to data compiled from an online cancer survivorship care planning tool presented at the 2014 ASCO Annual Meeting.
Patients with locally advanced nasopharyngeal cancer (NPC) do not benefit from the addition of neoadjuvant gemcitabine, carboplatin, and paclitaxel (GCP) to cisplatin chemoradiation.
Adding lapatinib to adjuvant trastuzumab for early-stage HER2-positive breast cancer does not improve patients' disease-free survival rates.
Exemestane + ovarian function suppression reduces recurrence risk in HR-positive early breast cancerJune 02, 2014
Adjuvant treatment with the aromatase inhibitor (AI) exemestane plus ovarian function suppression significantly reduced risk of disease recurrence in premenopausal women with hormone receptor (HR)-positive early breast cancer compared with tamoxifen plus ovarian function suppression (OFS), representing "a new treatment option for premenopausal women."
For premenopausal women with hormone receptor-positive early breast cancer, exemestane plus ovarian function suppression (OFS) is superior to tamoxifen plus OFS.
Upfront standard androgen deprivation therapy plus six cycles of docetaxel significantly improves overall survival compared with ADT alone in men with metastatic hormone-sensitive prostate cancer.
Baseline hypertension and BMI can affect worsening hypertension among patients administered vascular endothelial growth factor signaling pathway inhibitors, according to research presented at the 2014 ASCO Annual Meeting.
The presence of tumor-infiltrating lymphocytes ahead of treatment may help predict response to platinum-based chemotherapy in women with triple-negative breast cancer, according to a new study.
For the approximately 60,000 men in the United States with prostate cancer who are asymptomatic after radical primary treatment yet have a PSA relapse, it's safe to postpone androgen deprivation therapy, a study presented at the 2014 American Society of Clinical Oncology Annual Meeting concluded.
Depression and anxiety, not just inflammation, predict pain intensity and interference with daily life among women recovering from gynecologic cancer surgery.
A ginger extract, 6-gingerol, improves chemotherapy-induced nausea and vomiting (CINV), according to findings from a phase 2 randomized trial presented at the 2014 Annual ASCO Meeting.
Patients who express pretreatment concern about treatment symptoms such as nausea and memory problems tend to suffer higher symptom burdens during and after anticancer treatment, suggests research.
Treatment-related dysphagia symptoms are likely caused by internal lymphedema among patients with head and neck cancer, according to research presented at the 2014 ASCO Annual Meeting.
The site of metastatic tumors powerfully predicts overall survival (OS) among men with metastatic castration resistant prostate cancer (mCRPC), confirms a meta-analysis presented at the 2014 American Society of Clinical Oncology Annual Meeting.
Adding bevacizumab to neoadjuvant trastuzumab plus docetaxel in tumors with a low likelihood of pathologic complete response (pCR) increased the pCR rate from 24.0% to 43.8%, a phase 2 study concluded at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting.
Tumor biology-based therapy offers excellent outcomes among children with intermediate risk neuroblastoma, according to results from a prospective phase 3 reduction of therapy study.
Obese patients with gynecologic cancer are rarely counseled on weight loss, even though they expect to be, and report that such discussions would not offend them, according to research.
Expanding the National Cancer Institute (NCI) Community Cancer Centers Program within a rural community can increase the number of patients enrolled in clinical trials
Combination ridaforolimus + MK-2206 AKT inhibitor therapy yielded modest early clinical efficacy results for patients with low-RAS advanced breast cancer and PTEN-deficient prostate cancer.
Sign Up for Free e-newsletters
- Resolving Vaginal Dryness in Women With a History of Breast Cancer
- FDA Issues Warning for Rolapitant Injectable Emulsion in the Treatment of CINV
- Risk Factors for Arterial, Venous Thrombosis Differ in Polycythemia Vera
- Distinct Patterns of Shiny White Streaks Strong Indicator of Melanoma
- Survival Outcomes in Relapsed Hepatocellular Carcinoma Improved With Cabozantinib
- Pertuzumab Regimen Approved for Adjuvant, Neoadjuvant Therapy in Specific Breast Cancers
- Common Oncologic Emergencies That Occur With Multiple Myeloma
- Artificial Sweeteners and Cancer Risk (Fact Sheet)
- Blueberry Extract May Boost Efficacy of Radiotherapy for Cervical Cancer
- Dietary Estrogens Reduced Efficacy of Novel Breast Cancer Therapy
- When There Are No Words: Interpreting Patients' and Families' Subtle Messages
- Depression Predictive of Poor Survival Outcomes in Head and Neck Cancer
- Nearly One Third of Veterans Report Current Tobacco Use
- Priority Review of New Drug Application Granted to Apalutamide for CRPC
- Partial Response Achieved With Atezolizumab, Cobimetinib in Pretreated CRC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|